Trial reportThe Journal of infectious diseases2022
Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.
Trial report in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Dengue virus IgG and neutralizing antibody titers measured with standard and mature viruses are protective.Nature communications · 2025Article
- Dengue virus IgG and serotype-specific neutralizing antibody titers measured with standard and mature viruses are associated with protection.Research square · 2024Article
- 'Mix and Match' vaccination: Is dengue next?Vaccine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundIn the CYD14 (NCT01373281) and CYD15 (NCT01374516) dengue vaccine efficacy trials, month 13 neutralizing antibody (nAb) titers correlated inversely with risk of symptomatic, virologically confirmed dengue (VCD) between month 13 (1 month after final dose) and month 25. We assessed nAb titer as a correlate of instantaneous risk of hospitalized VCD (HVCD), for which participants were continually surveilled for 72 months.
methodsUsing longitudinal nAb titers from the per-protocol immunogenicity subsets, we estimated hazard ratios (HRs) of HVCD by current nAb titer value for 3 correlate/endpoint pairs: average titer across all 4 serotypes/HVCD of any serotype (HVCD-Any), serotype-specific titer/homologous HVCD, and serotype-specific titer/heterologous HVCD.
resultsBaseline-seropositive placebo recipients with higher average titer had lower instantaneous risk of HVCD-Any in 2- to 16-year-olds and in 9- to 16-year-olds (HR, 0.26 or 0.15 per 10-fold increase in average titer by 2 methods [95% confidence interval {CI}, .14-.45 and .07-.34, respectively]) pooled across both trials. Results were similar for homologous HVCD. There was evidence suggesting increased HVCD-Any risk in participants with low average titer (1:10 to 1:100) compared to seronegative participants (HR, 1.85 [95% CI, .93-3.68]).
conclusionsNatural infection-induced nAbs were inversely associated with hospitalized dengue, upon exceeding a relatively low threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.